Oral and Maxillofacial Surgery Cases (Dec 2020)

Gingival manifestation of a therapy-related acute myelomonocytic leukemia in a patient with previously treated with R–CHOP scheme for diffuse large B-cell lymphoma

  • Iacopo Panarese,
  • Stefano Lucà,
  • Andrea Ronchi,
  • Renato Franco,
  • Luigi Panico,
  • Carmelo Lo Faro,
  • Giuseppe Colella

Journal volume & issue
Vol. 6, no. 4
p. 100182

Abstract

Read online

Standard chemotherapy treatment for Diffuse large B-cell lymphoma (DLBCL), including cyclophosphamide, doxorubicin, vincristine and prednisone, in association with rituximab (CHOP-R) are considered associated to the development of secondary tumors. In this clinical setting, therapy-related myeloid neoplasms (t-MNs) represent one of the most common secondary tumors. In this case we describe, A 58-year-old patient diagnosed with DLBCL and treated with the CHOP-R therapeutic scheme, developed after 4 years a widespread gingival enlargement, diagnosed as acute myelomonocytic leukemia and then confirmed by overall clinical-pathological features. Therapy related neoplasms can be an aggressive complication of cytotoxic treatments of neoplastic and non-neoplastic diseases. Gingival hyperplasia could represent an early manifestation of these systemic pathologies.

Keywords